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ABSTRACT 
Cotrimoxazole reduces mortality in HIV-infected adults with tuberculosis (TB), and in 
vitro data suggest potential anti-mycobacterial activity of cotrimoxazole. We aimed to 
evaluate whether prophylaxis with cotrimoxazole is associated with a decreased risk of 
incident TB in SHCS participants. We determined the incidence of TB per 1000 person-
years from January 1992 to December 2012. Rates were analyzed separately in 
participants with current or no previous antiretroviral treatment (ART) using Poisson 
regression adjusted for CD4 cell count, sex, region of origin, injecting drug use, and 
age. 13,431 cohort participants contributed 107,549 person-years follow-up; 182 
patients had incident TB; 132 (73%) before and 50 (27%) after ART initiation. The 
multivariable incidence rate ratios for cumulative cotrimoxazole exposure per year for 
persons with no previous and current ART were 0.70 (95% CI 0.55-0.89) and 0.87 
(0.74-1.0) respectively. Cotrimoxazole may prevent the development of TB among HIV-
positive persons, especially among those with no previous ART.  
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INTRODUCTION  
Although tuberculosis (TB) can be successfully treated, it remains a leading cause of 
death among HIV-infected persons, particularly in low-income countries. A substantial 
proportion of deaths among patients with TB are caused by bacterial sepsis, and rates 
of bacterial pneumonia are several times higher among HIV-TB co-infected patients 
than in the HIV mono-infected population. Cotrimoxazole is a combination of 
trimethoprim and sulfamethoxazole that is widely used to treat bacterial infections 
including lower respiratory, gastrointestinal, urinary tract infections and P. jirovecii 
pneumonia (PCP). A randomized controlled trial showed that cotrimoxazole prophylaxis 
significantly reduced mortality in HIV-infected adults receiving TB treatment in Côte 
d’Ivoire 1. Other studies confirmed the effect of cotrimoxazole prophy- 
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[Figure 1: Cumulative previous cotrimoxazole exposure with bars classifying PYFU by 
latest CD4 class among participants with no previous ART (A) and those on current 
ART (B).] 
 
laxis on morbidity and mortality for combination antiretroviral treatment (ART)-naïve 
HIV-TB co-infected 2,3, and ART-experienced 4 persons. Furthermore, cotrimoxazole is 
strongly recommended as prophylaxis against PCP pneumonia in HIV-infected persons 
with CD4 cells counts below 200 cells/µL. 
 Recent in vitro studies suggested a potential antimicrobial effect of cotrimoxazole on 
Mycobacterium tuberculosis 5-9, whereby sulfamethoxazole seems to be the active 
compound in the fixed-dose combination 6. Moreover, sulfamethoxazole together with 
rifampicin appears to have a synergistic effect against M. tuberculosis 8. Whether 
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cotrimoxazole prophylaxis may prevent TB is uncertain. We therefore studied 
cumulative cotrimoxazole exposure as a determinant of incident TB among participants 
in the Swiss HIV Cohort Study (SHCS). Additionally, we considered total mortality as an 
endpoint, where we expected to find a beneficial effect of cotrimoxazole, in order to 
confirm adequate adjustment for various confounders. 
 
METHODS 
HIV-infected adults, aged ≥16 years, who attend outpatient clinics of seven cohort 
centres, affiliated regional hospitals, or private practitioners collaborating with the 
centres, are continuously enrolled in the prospective observational SHCS. The 
enrolment of participants is independent of social status. Healthcare in Switzerland is 
universal with a mandatory health insurance (including for immigrants and marginalized 
groups). Demographic, psychosocial, clinical, laboratory (immunologic and virologic 
parameters), and treatment information are collected at enrolment and thereafter 
completed every six months by physicians and study nurses 10. Local ethical 
committees approved the SHCS protocol, and written informed consent was obtained 
from all participants.  
 HIV-associated opportunistic infections including TB events are documented since 
1988, and data on immune reconstitution inflammatory syndrome (including TB IRIS) 
are collected since 2005. A TB event is diagnosed if there is culture positive evidence of 
Mycobacterium tuberculosis in a symptomatic patient. As part of a recent SHCS project 
by Fenner et al there was an endpoint validation of TB events 11. Purified protein 
derivate-based tuberculin skin testing (TST) is routinely performed in the SHCS, and 
latent TB treatment is initiated in TST-positives (defined as a skin induration of ≥ 5 mm) 
according to guidelines. We decided to exclude patients with previous TB treatment or 
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also latent TB treatment during follow-up, since latent TB treatment could be a major 
source of bias (if hypothesis correct, that the cumulative cotrimoxazole effect is based 
on treating latent TB infection).  
 Controlled trials identified the effectiveness of cotrimoxazole as secondary and 
primary PCP prophylaxis in 1992. Therefore, SHCS participants with at least two cohort 
visits between 1 January 1992 and 31  
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December 2012, without evidence of prevalent TB and no previous TB treatment, were 
included in the analyses. Incident TB and all-cause mortality, respectively, were 
calculated as the number of events divided by the number of person-years of follow-up 
(PYFU). Follow-up was counted from the first visit after January 1, 1992, to the earliest 
of the first event, the patient’s last cohort visit or 31 December 2012.  
 Poisson regression was used to model the incidence of TB or all-cause mortality 
separately in HIV-infected persons who had never yet received or had ever previously 
received combination ART (subsequently denoted no previous ART or current ART, 
respectively). We decided to specify separate models for those on no previous ART or 
current ART, because of differences in who would have been prescribed cotrimoxazole 
depending on ART status, and because of the potential for interactions between many 
covariates and ART in terms of effect on the outcomes. Because associations between 
cotrimoxazole intake and opportunistic infections or death are strongly confounded by 
CD4 cell count, which was the main determinant of prescription, we do not present 
univariable but bivariable associations adjusted for latest, time-updated square root 
CD4 cell count. Multivariable Poisson models for incident TB were adjusted for time-
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updated cumulative cotrimoxazole use, sex, region of origin, injecting drug use (IDU), 
and age >40 years. Cumulative cotrimoxazole was the primary exposure to avoid 
problems with reverse causality in patients prescribed cotrimoxazole for presumptive 
respiratory infection which was subsequently diagnosed as TB. We also considered 
ramp-functions in which the protective effect of cotrimoxazole increased over specified 
periods of time (1, 3, 6, 9, 12, 18 and 24 months) and then remained stable. Bivariable 
estimates of the protective effect for ramps up to 24 months did not indicate the 
presence of an inflection point (data not shown) which led us use cumulative 
cotrimoxazole use in the models. Interactions between cumulative cotrimoxazole 
exposure and CD4 categories were analyzed with a likelihood ratio test. Participants 
who stopped cotrimoxazole were analyzed based on the cumulative cotrimoxazole 
received. As an alternative, ART and its interaction with cotrimoxazole use were 
assessed in the multivariable model for TB incidence. In a sensitivity analysis we 
compared the TB incidence of patients who received cotrimoxazole with patients who 
received aerosolized pentamidine or dapsone assuming that they have similarly 
advanced HIV disease and that they can serve as a control group for the cotrimoxazole 
group. We calculated IRR for incident TB for cumulative pentamidine and cumulative 
dapsone use versus cumulative cotrimoxazole use.  
 Cumulative cotrimoxazole exposure, as a surrogate for the time being heavily 
immunosuppressed, is a confounding variable for death. Therefore we decided 1) to 
include current cotrimoxazole use, sex, region of origin, injecting drug use and age >40 
years in multivariable Poisson models for all-cause mortality and 2) to fit a second 
Poisson model for all-cause mortality with adjustment for current and cumulative 
cotrimoxazole exposure.  
 We used Stata (Version 12, StataCorp, College Station, Texas) for analyses. 
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RESULTS  
From 1992-2012, 14,589 SHCS participants contributed data. 1158 (8%) participants 
were excluded because of prevalent TB within 30 days of cohort registration (n=339), or 
any prior treatment of active or latent TB (n=819), leaving 13,431 SHCS participants in 
analyses. Baseline characteristics are shown in table 1. Median age at the first visit 
during the study period (baseline) was 35 years (interquartile range [IQR]: 30-42); 3,815 
(28%) individuals were women; 2,357 (18%) were from a region other than Europe, 
North America, or Australia; 2,697 (20%) had prior clinical AIDS. Nadir CD4 cell count 
was 273 (IQR 129-448) cells/µL. TST results were available for 8,980/ 13,431 (67%) of 
subjects and 365/ 8,980 (4%) had a positive test result. Participants with a positive test 
result were more likely to have a high CD4 cell count (median 466 [IQR 310-637] versus 
271 [131-440] cells/µL in those without). Median CD4 cell counts for Caucasians and for 
persons from other regions with a positive TST were 544 [343-695] and 336 cells/µL 
[249-489] cells/ µL, respectively. 95 (2%) patients who received cotrimoxazole vs. 270 
(5%) who never received cotrimoxazole had positive TST results; bivariate logistic 
regression confirmed that this difference was fully explained by the CD4 levels at the 
time of TST of 207 cells/µL [101-349] versus 437/µL [300-614] respectively (data not 
shown). 
 5265 (39%) persons took cotrimoxazole at some time during the study period for 
median 1.3 [IQR 0.50-2.8] years. Among participants with no previous ART 
cotrimoxazole exposure was 41,891 person years of follow up (PYFU), and among 
those with current ART cotrimoxazole exposure was 65,657 PYFU (figure 1). 1,406/ 
13,431 (10%) inhaled aerosolized pentamidine and 639 (5%) used pyrimethamine/ 
dapsone as second line prophylaxis against PCP pneumonia. 
 8 
 
 We observed 182 incident cases of TB. Incidence rates (IR) for TB among persons 
with current and no previous ART were 0.76 (95% confidence intervals, CI [0.58-1.00]), 
and 3.2 [2.7-3.7] per 1000 PYFU respectively.  
 Bivariable incidence rate ratios (IRR) for cumulative cotrimoxazole exposure/year 
were 0.71 [0.56-0.90] for persons with no previous ART, and 0.85 [0.72-1.0] for persons 
with current ART (table 2). Associations remained unchanged after multivariable 
adjustment for CD4, region of origin, IDU, and age >40y at baseline, but the impact of 
cumulative cotrimoxazole was slightly attenuated by ART use. In a combined analysis 
we included ART and its interaction with cotrimoxazole use in the multivariable model 
for TB incidence, also adjusted for square root CD4, region of origin, IDU and age. 
There was a strong protective effect of ART (IRR=0.31 (0.21-0.45)), and the 
associations with cotrimoxazole use were virtually unchanged (per year cotrimoxazole 
use pre-ART IRR=0.69 (0.54-0.88) and during ART IRR=0.89 (0.76-1.0)). We did not 
find an interaction between time since ART initiation and cumulative cotrimoxazole 
exposure (eg P=0.66 comparing 0-12 vs 12+ months). Including calendar period (1992-
1995; 1996-1999; 2000-2003; 2004-2007 and 2008-2012) in the multivariable models 
did not substantially change the estimate for cumulative cotrimoxazole exposure (no 
previous ART: IRR=0.77 [0.60-0.98], current ART: IRR=0.87 [0.74-1.0]). Including both 
current and cumulative cotrimoxazole exposure, suggested a similar protective effect of 
cumulative (no previous ART: IRR=0.55 [0.40-0.75]; current ART: IRR=0.84 [0.70-0.99]) 
but increased risk with current cotrimoxazole use (no previous ART: IRR=2.8 [1.7-4.4]; 
current ART: IRR=1.3 [0.61-2.7]), supporting the concern about reverse causality.  
 In sensitivity analyses including exposure to pentamidine and/or dapsone as well as 
cotrimoxazole, there was an association of reduced TB incidence with cumulative 
cotrimoxazole use (no previous ART: IRR 0.70 [0.55-0.87], P=0.003; current  
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[Table 1: Baseline characteristics of 13,431 HIV-infected participants stratified by co-
trimoxazole use] 
 
ART: IRR 0.86 [0.73-1.0], P=0.075), whereas no such evidence was present for 
cumulative aerosolized pentamidine (no previous ART: 0.86 [0.63-1.2], P=0.36; current 
ART: 0.11 [0.04-3.3], P=0.20) and for dapsone/ pyrimethamine (no previous ART: 0.83 
[0.45-1.5], P=0.55; current ART: 0.80 [0.38-1.7], P=57).  
 2,447 persons died, with IR 10 [9-11] and 42 [40-44] per 1000 PYFU in participants 
with current and no previous ART, respectively. The SHCS introduced detailed causes 
of death with ICD10 codes in 1999. One of the 1016 patients who died since 1999 had 
miliary tuberculosis as contributing cause of death; no other patients had TB as primary 
or secondary cause of death. Bi- and multivariable models showed lower death rates 
associated with current cotrimoxazole use irrespective of ART (all P<0.05) (table 2). 
Associations after multivariable adjustment remained unchanged in an analysis 
including current cotrimoxazole and cumulative cotrimoxazole exposure (all P<0.05). 
 We found several strong associations between co-variables and TB and all-cause 
mortality in the respective multivariable models (table 2). Risk of incident TB and all-
cause mortality decreased as current CD4 increased irrespective of ART status; 
persons from regions other than Europe, North America, or Australia had higher risks of 
incident TB and lower risks of all-cause mortality with current and no previous ART; and 
IDU and older age were associated with higher risks of all-cause mortality with current 
and no previous ART. 
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DISCUSSION  
We assessed incident TB and all-cause mortality, and studied associations with 
cumulative and current cotrimoxazole exposure among 13,431 SHCS participants 
prospectively followed for a 20-year-period. Cumulative cotrimoxazole exposure 
reduced the risk for incident TB among ART naïve and to a lesser extent in ART-
experienced persons, and current cotrimoxazole exposure reduced all-cause mortality 
after multivariable adjustment for CD4 cell count, region of origin other than Europe, 
North America, or Australia, IDU, and age >40 years at baseline, irrespective of 
antiretroviral treatment or not. 
 It is difficult to compare our results with other cohorts because the association 
between cotrimoxazole prophylaxis and incident TB does not appear to have been 
previously investigated. Other studies estimated either the effect of ART on TB 
incidence 12, or the effectiveness of cotrimoxazole prophylaxis on morbidity and 
mortality in HIV-infected ART-naïve persons 1-3 or those taking ART 4.  
 A recent large collaboration from Europe and the United States 12 found that TB 
incidence decreased after ART initiation except in older persons, and those with low 
CD4 cell counts. In the SHCS we also observed a marked decrease of TB incidence by 
year and among persons on ART 13.  
 Based on studies showing that cotrimoxazole reduces morbidity and mortality among 
ART-naïve persons with suspected or diagnosed TB 1-3, HIV-TB co-infected persons 
should receive cotrimoxazole prophylaxis. However, the mechanism through which 
cotrimoxazole reduces mortality in these patients is unclear, and until now, many 
assumed that cotrimoxazole would reduce deaths due to other HIV-related opportunistic 
infections, invasive bacterial disease, or malaria. We found a protective effect of 
cotrimoxazole on all-cause mortality and incident TB among SHCS participants, 
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suggesting that cotrimoxazole may have direct anti-tuberculosis effects. Such 
speculation is supported by several in vitro studies suggesting potential activity of 
cotrimoxazole against M. tuberculosis 5-9, and one case report of improvement of a TB 
patient with cotrimoxazole treatment 5. Of note, the addition of Cotrimoxaozle in 
combination with either isoniazid or rifampin prevented the emergence of drug 
resistance in vitro 9.  
 A recently published trial in HIV-infected children receiving long-term ART in sub-
Saharan Africa comparing continuing vs stopping cotrimoxazole prophylaxis found  that 
continued cotrimoxazole prophylaxis was beneficial with fewer hospitalizations and 
diagnostically-confirmed malaria cases 14. Interestingly, fewer cases of other infections 
and also fewer cases of TB occurred in the continued cotrimoxazole group (5/376 and 
15/382 TB events in the continued versus stopped cotrimoxazole group, respectively; 
hazard ratio 0.33 (95%CI 0.12-0.91), P=0.032). Whilst most diagnoses were 
presumptive, reflecting challenges in pediatric TB diagnosis, and bacterial co-infections 
are relatively common, this adds epidemiological evidence of a protective effect of 
cotrimoxazole on the incidence of TB among HIV-positive persons on ART. The effect 
of cotrimoxazole prophylaxis was also investigated among African adults starting ART in 
the DART cohort 4. Current cotrimoxazole prophylaxis reduced overall mortality, but 
only for the first 72 weeks on ART. There were no overall or long-term benefits from 
cotrimoxazole on pulmonary or extrapulmonary TB (data unpublished). However, this 
setting is very different from our study: 25% of DART participants reported previous TB 
at enrolment, very few participants received isoniazid prophylaxis, and TB incidence 
was around 10-fold higher than in those on ART in the SHCS. Similar results were 
obtained in another trial investigating the effect of early chemoprophylaxis with 
cotrimoxazole on morbidity and mortality in treatment naïve HIV-infected persons in 
 12 
 
Cote d’Ivoire15, where 11% of participants reported a history of TB at trial inclusion. 
17/271 (6%) of the cotrimoxazole group and 19/270 (7%) of the placebo group were 
hospitalized or died from TB (log-rank test P=0.6), but no information was available as 
to whether these hospitalizations/ deaths were incident cases or not. Lastly, a recent 
study 16 found no evidence that  
 
[Table 2: Risk of incident tuberculosis in 13,431 cohort participants based on bivariable 
and multivariable Poisson regression analyses] 
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[Table 3: All-cause mortality in 13,431 cohort participants based on bivariable and 
multivariable Poisson regression analyses] 
 
cotrimoxazole reduced TB incidence in another high-incidence setting (South Africa). 
Whilst this study is directly comparable with ours, since it excluded prevalent cases and 
considered only laboratory confirmed diagnosis, it only investigated the impact of 
current cotrimoxazole, which both we and they suggested could be associated with 
residual confounding. 
 Strengths of our study include its statistical power because of the large number of 
patient-years, and the prospective collection of incident TB and death. Additionally, we 
controlled for several cofactors known to be associated with incident TB or death. 
Several limitations should also be noted. First, Switzerland is a low incidence country for 
TB and TB incidence declined during the study period, which may limit the 
generalizability of our findings. This is one reason that 4% of participants had a positive 
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TST test result but received no isoniazid prophylaxis (and hence were included in the 
analysis), because this was not routinely provided when lifetime risk of incident TB was 
categorized as very low (Swiss origin, high CD4 cells, potentially BCG vaccination in the 
past). We were not able to include TST test results in our multivariable model, because 
TST results were only reliably done in 8989/13,431 (67%) of our participants and time-
updated TST results are not available in the SHCS. Second, cotrimoxazole is routinely 
used among SHCS participants with CD4 cells below 200 cells/ µl, and therefore the 
effect of cotrimoxazole and not being on ART is often confounded, which is why we 
conducted stratified analyses. Third, adherence to cotrimoxazole is not routinely 
assessed in the SHCS. Fourth, the SHCS does not collect information on homelessness 
and information on poverty, which are important social determinants of TB. However, 
only 0.5% of our patients were institutionalized in 2012, and the majority of IDUs in 
Switzerland, if still substance dependent, participate in opiate substitution programs and 
receive methadone or even heroin in healthcare settings. Fifth, microbiological isolates 
were not stored, so we could not perform susceptibility testing for cotrimoxazole among 
culture-positive TB samples among SHCS participants. 
 In conclusion, we found epidemiological evidence of a protective effect of 
cotrimoxazole prophylaxis on the incidence of manifest TB among SHCS participants. 
Cotrimoxazole prophylaxis may hence reduce the risk of TB in ART naïve persons. 
Additionally, there is a trend of a protective effect even among patients on ART. The 
clinical utility of our observation is uncertain for the developed world. In 2013 the liberal 
use of ART is promoted and clearly the higher priority than starting cotrimoxazole to 
reduce the risk of TB. It may however be more relevant in resource limited settings. 
Further studies, especially in low-income countries with a high burden of TB and HIV 
are needed to confirm our findings. 
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FIGURE 1 
 
 
 
FIGURE LEGEND 
Cumulative previous cotrimoxazole exposure with bars classifying PYFU by latest CD4 
class among those with no previous (Panel A) and current ART (Panel B) 
Abbreviations: PYFU, person years of follow up, ART, antiretroviral therapy 
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Table 1 Baseline characteristics of 13,431 HIV-infected participants stratified by cotrimoxazole use 
 Participants Never 
cotrimoxazole  
Ever 
cotrimoxazole 
P-value 
Participants, n (%) 13,431 (100) 8,166 (61) 5,265 (39)  
Year of baseline visit, median (IQR) 1998 (1993-2005) 2000 (1995-2006) 1996 (1992-2001) <0.001 
Female, n (%) 3,815 (100) 2,293 (60) 1,522 (40) 0.299 
Age, median years (IQR) 35 (30-42) 34 (29-41) 35 (30-43) <0.001 
Nadir CD4, cells/ µl, median (IQR)  273 (129-448) 355 (228-525) 150 (61-274) <0.001 
Nadir CD4 <200 cells/ µL, n (%) 4,602 (100) 1,510 (33) 3,092 (67) <0.001 
Riskgroups and respective 
percentage with nadir CD4 <200/ 
cells µL 
    
Heterosexuals, n (%) 4,521 (100) 2,292 (60) 1,829 (40) <0.001 
Nadir CD4 <200 cells/ µL, n (%) 1,697 (100) 510 (30) 1187 (70) <0.001 
IDU, n (%) 3,108 (100) 1,591 (51) 1,517 (49)  
Nadir CD4 <200 cells/ µL, n (%) 1,084 (100) 349 (32) 735 (68) <0.001 
MSM, n (%) 5,271 (100) 3,583 (68) 1,688 (32)  
Nadir CD4 <200 cells/ µL, n (%) 1,618 (100) 597 (37) 1021 (63) <0.001 
Other, n (%) 531 (100) 300 (57) 231 (44)  
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Nadir CD4 <200 cells/ µL, n (%) 203 (100) 54 (27) 149 (73) <0.001 
Ethnicity     
Caucasian
1
, n (%) 11,074 (100) 6,679 (60) 4,395 (40) 0.012 
Other, n (%) 2,357 (100) 1,487 (64) 870 (37)  
CDC Stage     
A, n (%) 8,497 (100) 6,111 (72) 2,386 (29) <0.001 
B, n (%) 2,237 (100) 1,131 (51) 1,106 (49)  
C, n (%) 2,697 (100) 924 (34) 1,773 (66)  
Nadir CD4, cells/ µl, median (IQR)  273 (129-448) 355 (228-525) 150 (61-274) <0.001 
TST at enrollment     
Test performed, n (%) 8,989 (100) 5,088 (62) 3901 (74) <0.001 
TST positive, n (%) 365 (100) 270 (5) 95 (2) <0.001 
1
 “Caucasian” denotes SHCS participants from north-western Europe, North America and Australia 
Abbrevations: IDU, intravenous drug use; MSM, men who have sex with men; TST, tuberculin skin test 
 
 
 22 
 
Table 2 Risk of incident tuberculosis (Panel A) and all-cause mortality (Panel B): bivariable and multivariable poisson regression 
analyses in 13,431 cohort participants 
Panel A 
Covariables 
No previous ART 
132 events during 41,891 person-years of follow-up 
Current ART 
50 events during 65,657 person-years of follow-up  
IRR bivariable 
models (95% CI)
3
 
P-value IRR multivariable 
models (95% CI) 
P-value IRR bivariable 
models (95% CI)
4
 
P-value IRR multivariable 
models (95% CI) 
P-value 
         
Cumulative Cotrimoxazole 
use per year 
0.71 (0.56-0.90) 0.005 0.70 (0.55-0.89) 0.004 0.85 (0.72-1.00) 0.05 0.87 (0.74-1.0) 0.088 
Square root CD4 [cells/µl] 0.90 (0.88-0.92) <0.001 0.88 (0.86-0.90) <0.001 0.85 (0.82-0.89) <0.001 0.84 (0.80-0.87) <0.001 
Region of origin
1
 3.4 (2.3-5.0) <0.001 3.8 (2.5-5.7) <0.001 5.5 (3.1-9.6) <0.001 4.2 (2.3-7.6) <0.001 
IDU 1.1 (0.77-1.6) 0.625 1.4 (0.95-2.1) 0.092 0.31 (0.12-0.78) 0.013 0.46 (0.17-1.2) 0.113 
Age > 40 years
2
 0.71 (0.46-1.1) 0.117 0.85 (0.54-1.3) 0.480 0.54 (0.28-1.1) 0.074 0.61 (0.31-1.2) 0.155 
 
Panel B 
Covariables 
No previous ART 
based on 1769 events and 42,229 person years of follow-up 
Current ART 
based on 678 events and 66,419 person years of follow- up 
IRR bivariable 
models (95% CI)
3
 
P-value IRR multivariable 
models (95% CI) 
P-value IRR bivariable 
models (95% CI)
4
 
P-value IRR multivariable 
models (95% CI) 
P-value 
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Current cotrimoxazole use 0.05 (0.04-0.07) <0.001 0.05 (0.04-0.07) <0.001 0.18 (0.13-0.24) <0.001 0.18 (0.13-0.23) <0.001 
Square root CD4 [cells/µl] 0.79 (0.79-0.80) <0.001 0.78 (0.77-0.78) <0.001 0.87 (0.86-0.88) <0.001 0.84 (0.83-0.85) <0.001 
Region of origin
1
 0.61 (0.50-0.76) <0.001 0.65 (0.52-0.80) <0.001 0.35 (0.26-0.48) <0.001 0.48 (0.35-0.66) 0.001 
IDU 1.1 (0.97-1.2) 0.154 1.1 (1.0-1.3) 0.013 1.9 (1.6-2.2) <0.001 2.1 (1.8-2.5) <0.001 
Age >40 years
2
 1.4 (1.2-1.5) <0.001 1.6 (1.4-1.7) <0.001 1.6 (1.4-1.9) <0.001 2.0 (1.7-2.3) <0.001 
 
1
Region of origin other than Europe, North America, or Australia 
2
Age at baseline (1. January 1992 or at registration in the Swiss HIV Cohort Study whichever is the later) 
3
The IRR bivariable models were adjusted for time-updated CD4 cell count. 
Abbreviations: CI, confidence intervals; IRR, incidence rate ratio; ART, antiretroviral treatment. IDU, intravenous drug use 
